Cubist Systematic Strategies LLC Makes New Investment in Myovant Sciences Ltd (NYSE:MYOV)

Share on StockTwits

Cubist Systematic Strategies LLC acquired a new position in Myovant Sciences Ltd (NYSE:MYOV) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 36,479 shares of the company’s stock, valued at approximately $330,000.

Other hedge funds also recently made changes to their positions in the company. Tower Research Capital LLC TRC bought a new stake in Myovant Sciences in the second quarter worth about $60,000. Northern Trust Corp bought a new stake in Myovant Sciences in the second quarter worth about $105,000. Virtus ETF Advisers LLC bought a new stake in Myovant Sciences in the second quarter worth about $279,000. BlackRock Inc. raised its position in Myovant Sciences by 59.1% in the second quarter. BlackRock Inc. now owns 44,637 shares of the company’s stock worth $404,000 after acquiring an additional 16,580 shares during the period. Finally, Swiss National Bank raised its position in Myovant Sciences by 134.0% in the second quarter. Swiss National Bank now owns 73,000 shares of the company’s stock worth $661,000 after acquiring an additional 41,800 shares during the period. 40.29% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have recently issued reports on the stock. Svb Leerink assumed coverage on shares of Myovant Sciences in a research report on Monday, August 19th. They issued an “outperform” rating and a $26.00 price target on the stock. Cowen reissued a “buy” rating on shares of Myovant Sciences in a research report on Friday, September 6th. Goldman Sachs Group assumed coverage on shares of Myovant Sciences in a research report on Wednesday, August 28th. They issued a “buy” rating and a $20.00 price target on the stock. Leerink Swann assumed coverage on shares of Myovant Sciences in a research report on Monday, August 19th. They issued an “outperform” rating and a $26.00 price target on the stock. Finally, Zacks Investment Research lowered shares of Myovant Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $22.18.

NYSE MYOV opened at $4.83 on Friday. The company’s 50 day moving average is $6.40 and its 200-day moving average is $11.25. Myovant Sciences Ltd has a 12-month low of $4.57 and a 12-month high of $26.02. The company has a quick ratio of 3.42, a current ratio of 3.42 and a debt-to-equity ratio of 1.24. The firm has a market cap of $432.88 million, a P/E ratio of -1.18 and a beta of 0.90.

Myovant Sciences (NYSE:MYOV) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $0.06. Equities analysts expect that Myovant Sciences Ltd will post -3.13 EPS for the current year.

About Myovant Sciences

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

See Also: What is the definition of a trade war?

Want to see what other hedge funds are holding MYOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myovant Sciences Ltd (NYSE:MYOV).

Institutional Ownership by Quarter for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

CX Institutional Trims Stock Holdings in XPO Logistics Inc
CX Institutional Trims Stock Holdings in XPO Logistics Inc
Cubist Systematic Strategies LLC Sells 638 Shares of Teleflex Incorporated
Cubist Systematic Strategies LLC Sells 638 Shares of Teleflex Incorporated
1,507 Shares in Paychex, Inc.  Bought by CX Institutional
1,507 Shares in Paychex, Inc. Bought by CX Institutional
Cubist Systematic Strategies LLC Takes $325,000 Position in Pagerduty Inc
Cubist Systematic Strategies LLC Takes $325,000 Position in Pagerduty Inc
Cubist Systematic Strategies LLC Makes New Investment in Myovant Sciences Ltd
Cubist Systematic Strategies LLC Makes New Investment in Myovant Sciences Ltd
Cubist Systematic Strategies LLC Acquires 11,016 Shares of TechnipFMC PLC
Cubist Systematic Strategies LLC Acquires 11,016 Shares of TechnipFMC PLC


© 2006-2019 Ticker Report